Biotech | November 22, 2024
Merck Life Science India ink MoU with GeNext Genomics
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Subscribe To Our Newsletter & Stay Updated
